Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 197-205

  Pasqualetti, Giuseppe ^a   Ricciardi, Simona ^b   Mey, Valentina ^b   Del Tacca, Mario ^a,b   Danesi, Romano ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Drug interaction; Gemcitabine; Lung cancer; NSCLC; Sorafenib

Indexed keywords

COMPLEMENTARY DNA; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RNA; SORAFENIB;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIDINES; RAF KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 80053620899     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.03.003     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Tyson L.B. Non-small cell lung cancer: new hope for a chronic illness. Oncol Nurs Forum 2007, 34:963-970.
3. Scagliotti G., Novello S. Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 2003, 42:47-51.
4. Tortora G., Caputo R., Damiano V., Melisi D., Bianco R., Fontanini G., et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003, 9:866-871.
5. Ciardiello F., Troiani T., Bianco R., Orditura M., Morgillo F., Martinelli E., et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006, 17:109-114.
6. Maione P., Gridelli C., Troiani T., Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006, 11:274-284.
7. Morabito A., De Maio E., Di Maio M., Normanno N., Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006, 11:753-764.
8. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2005, 64:7099-7109.
9. Crawford Y., Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapy. Trends Pharmacol Sci 2009, 30(12):624-630.
10. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994, 4:82-89.
11. Danesi R., Pasqualetti G., Giovannetti E., Del Tacca M. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer. J Thorac Oncol 2007, 2:27-30.
12. Dal Lago L., D'Hondt V., Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008, 13:845-858.
13. Blumenschein G. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol 2008, 3:124-127.
14. Kindler H.L., Wroblewski K., Wallace J.A., Hall M.J., Locker G., Nattam S., et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs 2010 Aug 28.
15. Vincent P., Zhang X., Chen C.M., Lantz L., Rembiesa C., Polony B., et al. Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, vinorelbine, gemcitabine or doxorubicin. Proc Am Assoc Cancer Res 2003, 44:164.
16. Ricciardi S., Mey V., Nannizzi S., Pasqualetti G., Crea F., Danesi R., et al. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy 2010, 56:303-312.
17. Hoffmann K., Franz C., Xiao Z., Mohr E., Serba S., Büchler M.W., et al. Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. Anticancer Res 2010, 30(November (11)):4503-4508.
18. Welch S.A, Hirte H., Elit L., Schilder R.J., Wang L., Macalpine K., et al. CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-a trial of the PMH phase II consortium. J Clin Oncol 2007, 25:5519.
19. Bellmunt J., Trigo J.M., Calvo E., Carles J., Pérez-Gracia J.L., Rubió J., et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010 Apr, 11(4):350-357.
20. Al-Mulla F., Hagan S., Behbehani A.I., Bitar M.S., George S.S., Going J.J., et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 2006, 24:5672-5679.
21. Giovannetti E., Mey V., Danesi R., Mosca I., Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004, 10:2936-2943.
22. Tai C.J., Wu A.T., Chiou J.F., Jan H.J., Wei H.J., Hsu C.H., et al. The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging. BMC Cancer 2010, 10:95.
23. Panka D.J., Wang W., Atkins M.B., Mier J.W. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006, 66:1611-1619.
24. Rahmani M., Davis E.M., Bauer C., Dent P., Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005, 280:35217-35227.
25. Bold R.J., Chandra J., McConkey D.J. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999, 6:279-285.
26. Plastaras J.P., Kim S.H., Liu Y.Y., Dicker D.T., Dorsey J.F., McDonough J., et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007, 67:9443-9454.
27. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
28. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009, 8:118.
29. Yasuda A., Sawai H., Takahashi H., Ochi N., Matsuo Y., Funahashi H., et al. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer 2006, 5:46.
30. Keller E.T. Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). Anticancer Drugs 2004, 15:663-669.
31. Chatterjee D., Bai Y., Wang Z., Beach S., Mott S., Roy R., et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 2004, 279:17515-17523.